

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 4.1 Revision Date: 02.10.2020 SDS Number: 23064-00017 Date of last issue: 23.03.2020
Date of first issue: 17.10.2014

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Montelukast Tablet Formulation

Manufacturer or supplier's details

Company : Organon & Co.
Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil B-2220
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Not a hazardous substance or mixture.

GHS label elements in accordance with ABNT NBR 14725 Standard

Not a hazardous substance or mixture.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		≥ 30 -< 50
Montelukast	151767-02-1	Eye irritation, Category 2B	≥ 5 -< 10
Magnesium stearate	557-04-0		≥ 1 -< 5
Titanium dioxide	13463-67-7	Carcinogenicity (Inhalation), Category 2	$\geq 0,1$ -< 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Montelukast Tablet Formulation

Version 4.1 Revision Date: 02.10.2020 SDS Number: 23064-00017 Date of last issue: 23.03.2020
 Date of first issue: 17.10.2014

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Montelukast	151767-02-1	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m ³ (Titanium dioxide)	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 4.1 Revision Date: 02.10.2020 SDS Number: 23064-00017 Date of last issue: 23.03.2020
Date of first issue: 17.10.2014

Appearance	:	tablet
Color	:	colored
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

Montelukast:

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg LD50 (Mouse): > 5.000 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
---------------------	---	--

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6,82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Montelukast:**

Species : Rabbit
Result : Mild skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Montelukast:**

Species : Rabbit
Result : Severe irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Montelukast:**

Remarks : No data available

Magnesium stearate:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative
 Remarks : Based on data from similar materials

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
 Routes of exposure : Skin contact
 Species : Mouse
 Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
 cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster fibroblasts
 Result: negative

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: negative

Test Type: Alkaline elution assay
 Test system: rat hepatocytes
 Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
 Species: Mouse
 Cell type: Bone marrow
 Application Route: Oral
 Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
 Species: Mouse
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Montelukast:

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Montelukast Tablet Formulation

Version 4.1 Revision Date: 02.10.2020 SDS Number: 23064-00017 Date of last issue: 23.03.2020
Date of first issue: 17.10.2014

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

Titanium dioxide:

Species : Rat
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : positive
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Montelukast:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL: 200 mg/kg body weight
Symptoms: Reduced fertility

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 100 mg/kg body weight
Symptoms: Reduced fertility

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
NOAEL : ≥ 9.000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Montelukast:

Species : Monkey, male and female
NOAEL : 150 - 300 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat
 NOAEL : 24.000 mg/kg
 Application Route : Ingestion
 Exposure time : 28 Days

Species : Rat
 NOAEL : 10 mg/m³
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Montelukast:**

Skin contact : Remarks: May irritate skin.
 Eye contact : Symptoms: Severe irritation
 Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,
 Headache, Cough, Abdominal pain, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Montelukast:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0,0778 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : EC50 (*Daphnia magna* (Water flea)): > 0,0675 mg/l
 aquatic invertebrates : Exposure time: 48 h
 Method: OECD Test Guideline 202
 Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 100
 plants : mg/l
 Exposure time: 72 h

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,073 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0,0816 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,23 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (*Skeletonema costatum* (marine diatom)): > 10.000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1.000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Montelukast:

Biodegradability : Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21,7 h)

Magnesium stearate:

Biodegradability : Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Montelukast:**

Partition coefficient: n-octanol/water : log Pow: > 4,3

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.1	02.10.2020	23064-00017	Date of first issue: 17.10.2014

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8